Explore

Evergreen Daily Evergreen Daily
How to Compare Vitamin D Supplements Without Overpaying

How to Compare Vitamin D Supplements Without Overpaying

Learn how to choose the right Vitamin D supplement by comparing forms, dosage, third-party testing, and the true cost per dose to ensure you get the best value.
Evergreen Daily Evergreen Daily
9 Label Details to Check Before Buying Hair Growth Vitamins

9 Label Details to Check Before Buying Hair Growth Vitamins

Learn how to read hair growth vitamin labels to make informed choices. This guide covers dosages, proprietary blends, and third-party testing.
Evergreen Daily Evergreen Daily
When Vitamin D Supplements May Help Fill a Nutritional Gap

When Vitamin D Supplements May Help Fill a Nutritional Gap

Learn about the key risk factors for Vitamin D deficiency, from your location and skin tone to diet, and find out if you might need a supplement.
Evergreen Daily Evergreen Daily
What to Know Before Adding Vitamin D to Your Routine

What to Know Before Adding Vitamin D to Your Routine

Thinking about taking a vitamin D supplement? Here’s how to understand dosage, testing, and the potential risks before you start your routine.
Trendline Trendline
AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted
Rapid Read Rapid Read
FDA Advisory Committee Recommends Loosening Restrictions on Popular Peptides Amid Safety Concerns

FDA Advisory Committee Recommends Loosening Restrictions on Popular Peptides Amid Safety Concerns

A U.S. Food and Drug Administration (FDA) advisory committee has recommended easing restrictions on certain popular peptides, which are marketed for benefits such as anti-aging and muscle recovery. These peptides, often available through a regulatory gray market, have been identified by the FDA as posing significant safety risks due to limited human research supporting their safety and effectiveness. The committee's vote has sparked controversy in medical circles, as many of these peptides lack adequate human clinical evidence for their marketed uses. The peptides under review include Body Protection Compound-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, which are promoted for various health benefits but have limited supporting evidence from human trials.
Rapid Read Rapid Read
Baxter Recalls Cefazolin Lot Due to Contamination, Impacting Surgical Antibiotic Supply

Baxter Recalls Cefazolin Lot Due to Contamination, Impacting Surgical Antibiotic Supply

Baxter International has issued a recall for a lot of Cefazolin in Dextrose Injection, USP, due to the presence of cardboard particles in the solution. This antibiotic is widely used to prevent infections during surgeries. The recall affects Lot LD175708, which was distributed across the United States between March 25 and June 30, 2025, with an expiration date of February 14, 2027. The recall is significant because cefazolin is already listed as being in short supply by the FDA. The presence of foreign material in the injectable product poses risks such as pulmonary emboli and other serious health issues. Hospitals and distributors have been notified to check their inventories, and the recall primarily impacts hospital pharmacies and home infusion patients.
Rapid Read Rapid Read
FDA Panel Recommends Broader Access to Peptide Therapies Despite Safety Concerns

FDA Panel Recommends Broader Access to Peptide Therapies Despite Safety Concerns

A federal advisory panel has recommended that the Food and Drug Administration (FDA) reclassify several peptide therapies, potentially allowing specialized pharmacies in the U.S. to offer them. The panel's decision, made during a two-day meeting, supports the use of peptides for various health benefits, despite the lack of large, well-controlled human trials. The peptides under consideration include BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax, with Emideltide being the only one not endorsed. The FDA typically follows advisory committee recommendations, although it is not required to do so.
Rapid Read Rapid Read
FDA Approves Otsuka's SIMTRIYO for ADHD Treatment in Adults and Children

FDA Approves Otsuka's SIMTRIYO for ADHD Treatment in Adults and Children

Otsuka Pharmaceutical Co., Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for SIMTRIYO® (centanafadine), a new treatment for attention-deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older. SIMTRIYO is the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) approved for this purpose. The approval is based on four pivotal Phase 3 clinical trials that demonstrated significant improvements in ADHD symptoms. The drug will be available later this year following scheduling by the U.S. Drug Enforcement Administration (DEA).
Rapid Read Rapid Read
FDA Advisers Vote on Peptides for Drug Compounding List, Await Final Decision

FDA Advisers Vote on Peptides for Drug Compounding List, Await Final Decision

FDA advisers have narrowly voted to add six peptides to a drug compounding list, a decision that is non-binding and requires final approval from the FDA. This vote is part of ongoing efforts to regulate and expand the list of substances that can be legally compounded by pharmacies. The decision comes amid growing interest in the use of peptides for various therapeutic purposes, including their potential benefits in treating chronic conditions. The FDA's final decision will determine whether these peptides can be compounded, impacting pharmacies and patients seeking alternative treatment options.
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Rapid Read Rapid Read
FDA Announces Educational Webinar on Expedited IND Pilot Program

FDA Announces Educational Webinar on Expedited IND Pilot Program

The U.S. Food and Drug Administration (FDA) has announced an educational webinar scheduled for August 6, 2026, to discuss the proposed Expedited Investigational New Drug (IND) pilot program. This initiative aims to accelerate the transition from drug identification to first-in-human clinical trials. The program will establish a network of Qualified Research Institutions (QRIs), including academic medical centers, healthcare networks, and contract research organizations, to partner with sponsors in developing and reviewing protocols for IND submissions. The webinar will provide stakeholders with detailed information about the program's objectives and solicit feedback.